TrialNature medicine2021

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

E A Rozeman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.